Page 608 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

586 PART IV Specific Malignancies in the Small Animal Patient

11. Galac S, Kooistra HS, Voorhout G, et al.: Hyperadrenocorticism 30. Duesberg CA, Feldman EC, Nelson RW, et al.: Magnetic reso-
in a dog due to ectopic secretion of adrenocorticotropic hormone, nance imaging for diagnosis of pituitary macrotumors in dogs, J
Domest Anim Endocrinol 28:338–348, 2005. Am Vet Med Assoc 206:657–662, 1995.
VetBooks.ir 12. Behrend EN, Kooistra HS, Nelson R, et al.: Diagnosis of spontane- 31. Bertoy EH, Feldman EC, Nelson RW, et al.: One-year follow-up
evaluation of magnetic resonance imaging of the brain in dogs with
ous canine hyperadrenocorticism: 2012 ACVIM consensus state-
ment (small animal), J Vet Intern Med 27:1292–1304, 2013.
13. Gould SM, Baines EA, Mannion PA, et al.: Use of endogenous pituitary-dependent hyperadrenocorticism, J Am Vet Med Assoc
208:1268–1273, 1996.
ACTH concentration and adrenal ultrasonography to distinguish 32. Taoda T, Hara Y, Masuda H, et al.: Magnetic resonance imaging
the cause of canine hyperadrenocorticism, J Small Anim Pract assessment of pituitary posterior lobe displacement in dogs with
42:113–121, 2001. pituitary-dependent hyperadrenocorticism, J Vet Med Sci 73:725–
14. Grooters AM, Biller DS, Theisen SK, et al.: Ultrasonographic char- 731, 2011.
acteristics of the adrenal glands in dogs with pituitary-dependent 33. Zhao Q, Lee S, Kent M, et al.: Dynamic contrast-enhanced mag-
hyperadrenocorticism: comparison with normal dogs, J Vet Intern netic resonance imaging of canine brain tumors, Vet Radiol Ultra-
Med 10:110–115, 1996. sound 51:122–129, 2010.
15. Besso JG, Penninck DG, Gliatto JM: Retrospective ultrasono- 34. Nelson RW, Ihle SL, Feldman EC: Pituitary macroadenomas and
graphic evaluation of adrenal lesions in 26 dogs, Vet Radiol Ultra- macroadenocarcinomas in dogs treated with mitotane for pituitary-
sound 38:448–455, 1997. dependent hyperadrenocorticism - 13 Cases (1981-1986), J Am Vet
16. Hoerauf A, Reusch C: Ultrasonographic characteristics of both Med Assoc 194:1612–1617, 1989.
adrenal glands in 15 dogs with functional adrenocortical tumors, J 35. Feldman EC, Nelson RW: Canine hyperadrenocorticism (Cush-
Am Anim Hosp Assoc 35:193–199, 1999. ing’s syndrome). In Feldman EC, Nelson RW, editors: Canine and
17. Benchekroun G, de Fornel-Thibaud P, Pineiro MIR, et al.: Ultra- feline endocrinology and reproduction, ed 3, St. Louis, 2004, Saun-
sonography criteria for differentiating ACTH dependency from ders, pp 252–357.
ACTH independency in 47 dogs with hyperadrenocorticism and 36. Theon AP, Feldman EC: Megavoltage irradiation of pituitary
equivocal adrenal asymmetry, J Vet Intern Med 24:1077–1085, macrotumors in dogs with neurologic signs, J Am Vet Med Assoc
2010. 213:225–231, 1998.
18. Greco DS, Peterson ME, Davidson AP, et al.: Concurrent pituitary 37. Bosje JT, Rijnberk A, Mol JA, et al.: Plasma concentrations of
and adrenal tumors in dogs with hyperadrenocorticism: 17 cases ACTH precursors correlate with pituitary size and resistance to
(1978-1995), J Am Vet Med Assoc 214:1349–1353, 1999. dexamethasone in dogs with pituitary-dependent hyperadrenocor-
19. Anderson CR, Birchard SJ, Powers BE, et al.: Surgical treatment ticism, Domest Anim Endocrinol 22:201–210, 2002.
of adrenocortical tumors: 21 cases (1990-1996), J Am Anim Hosp 38. Granger N, de Fornel P, Devauchelle P, et al.: Plasma pro-opi-
Assoc 37:93–97, 2001. omelanocortin, pro-adrenocorticotropin hormone, and pituitary
20. Kyles AE, Feldman EC, De Cock HE, et al.: Surgical management adenoma size in dogs with Cushing’s disease, J Vet Intern Med
of adrenal gland tumors with and without associated tumor thrombi 19:23–28, 2005.
in dogs: 40 cases (1994-2001), J Am Vet Med Assoc 223:654–662, 39. Ramsey IK: Trilostane in dogs, Vet Clin North Am Small Anim Pract
2003. 40:269–283, 2010.
21. Morandi F, Mays JL, Newman SJ, et al.: Imaging diagnosis-bilat- 40. Kintzer PP, Peterson ME: Mitotane (o,p’-DDD) treatment of 200
eral adrenal adenomas and myelolipomas in a dog, Vet Radiol Ultra- dogs with pituitary-dependent hyperadrenocorticism, J Vet Intern
sound 48:246–249, 2007. Med 5:182–190, 1991.
22. Lang JM, Schertel E, Kennedy S, et al.: Elective and emergency sur- 41. Neiger R, Ramsey I, O’Connor J, et al.: Trilostane treatment of
gical management of adrenal gland tumors: 60 cases (1999-2006), J 78 dogs with pituitary-dependent hyperadrenocorticism, Vet Rec
Am Anim Hosp Assoc 47:428–435, 2011. 150:799–804, 2002.
23. Nabeta R, Osada H, Ogawa M, et al.: Clinical and pathological fea- 42. Vaughan MA, Feldman EC, Hoar BR, et al.: Evaluation of twice-
tures and outcome of bilateral incidental adrenocortical carcinomas daily, low-dose trilostane treatment administered orally in dogs
in a dog, J Vet Med Sci 79:1489–1493, 2017. with naturally occurring hyperadrenocorticism, J Am Vet Med Assoc
24. Voorhout G, Stolp R, Lubberink AA, et al.: Computed tomog- 232:1321–1328, 2008.
raphy in the diagnosis of canine hyperadrenocorticism not sup- 43. Barker EN, Campbell S, Tebb AJ, et al.: A comparison of the survival
pressible by dexamethasone, J Am Vet Med Assoc 192:641–646, times of dogs treated with mitotane or trilostane for pituitary-depen-
1988. dent hyperadrenocorticism, J Vet Intern Med 19:810–815, 2005.
25. Bertolini G, Furlanello T, Drigo M, et al.: Computed tomo- 44. de Bruin C, Hanson JM, Meij BP, et al.: Expression and functional
graphic adrenal gland quantification in canine adrenocorticotroph analysis of dopamine receptor subtype 2 and somatostatin recep-
hormone-dependent hyperadrenocorticism, Vet Radiol Ultrasound tor subtypes in canine cushing’s disease, Endocrinology 149:4357–
49:449–453, 2008. 4366, 2008.
26. van der Vlugt-Meijer RH, Meij BP, van den Ingh TS, et al.: 45. Castillo V, Theodoropoulou M, Stalla J, et al.: Effect of SOM230
Dynamic computed tomography of the pituitary gland in dogs (pasireotide) on corticotropic cells: action in dogs with Cushing’s
with pituitary-dependent hyperadrenocorticism, J Vet Intern Med disease, Neuroendocrinology 94:124–136, 2011.
17:773–780, 2003. 46. Lottati M, Bruyette DS: Outcomes of the addition of pasireotide
27. van der Vlugt-Meijer RH, Meij BP, Voorhout G: Dynamic helical to traditional adrenal-directed treatment for dogs with pituitary-
computed tomography of the pituitary gland in healthy dogs, Vet dependent hyperadrenocorticism secondary to macroadenoma: 9
Radiol Ultrasound 48:118–124, 2007. cases (2013-2015), J Am Vet Med Assoc 252:1403–1408, 2018.
28. Auriemma E, Barthez PY, van der Vlugt-Meijer RH, et al.: Com- 47. Braddock JA, Church DB, Robertson ID, et al.: Inefficacy of selegi-
puted tomography and low-field magnetic resonance imaging of line in treatment of canine pituitary-dependent hyperadrenocorti-
the pituitary gland in dogs with pituitary-dependent hyperadreno- cism, Aust Vet J 82:272–277, 2004.
corticism: 11 cases (2001-2003), J Am Vet Med Assoc 235:409–414, 48. Castillo VA, Gomez NV, Lalia JC, et al.: Cushing’s disease in dogs:
2009. cabergoline treatment, Res Vet Sci 85:26–34, 2008.
29. Bertoy EH, Feldman EC, Nelson RW, et al.: Magnetic resonance 49. Rijnberk A, Mol JA, Kwant MM, et al.: Effects of bromocriptine
imaging of the brain in dogs with recently diagnosed but untreated on corticotrophin, melanotrophin and corticosteroid secretion in
pituitary-dependent hyperadrenocorticism, J Am Vet Med Assoc dogs with pituitary-dependent hyperadrenocorticism, J Endocrinol
206:651–656, 1995. 118:271–277, 1988.